鹅IL-2基因在大肠杆菌中的表达及其可溶性单体的分离

将去除信号肽编码序列的鹅IL-2基因克隆到原核表达载体pET-28a (+), 构建了重组表达质粒pET-28a (+)-goIL-2, 转化大肠杆菌BL21(DE3)感受态细胞, 经IPTG诱导, 实现了重组鹅IL-2(rgoIL-2)蛋白在大肠杆菌中的表达。SDS-PAGE和Western-blotting分析显示, 表达蛋白的分子量约为15.0 kD, 能被抗鹅IL-2单克隆抗体特异识别。可溶性分析表明表达蛋白大部分以包涵体形式存在, 部分以可溶形式存在, 非变性电泳可见可溶性蛋白存在单体和多聚体组分。镍柱亲和层析法纯化的rgoIL-2蛋白过滤后, 利用?KTA FPLC(快速蛋白分离纯化系统)进行逐级分离, 非变性电泳可见单一的鹅IL-2可溶性蛋白单体。体外生物学活性分析显示鹅IL-2可溶性蛋白单体能刺激鹅淋巴细胞增殖。这为进一步研究鹅IL-2的生物学功能及其临床应用奠定基础。     

Ⅰ型单纯疱疹病毒 gD基因片段的高效表达及抗原性分析

目的 获得高表达的Ⅰ型单纯疱疹病毒(HSV)被膜糖蛋白gD（简称gD1）基因的工程菌。方法 通过计算机分析,筛选出疱疹病毒gD1中优势抗原决定簇的基因片段。将克隆的基因片段插入表达载体pTrxA内,转化大肠杆菌Rosetta,以异丙基-β-D-硫代半乳糖苷诱导表达。十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)分析表达产物。　结果　PCR扩增出约930bp的gD1编码基因目的片段,与预期片段大小相符,经测序鉴定无基因突变;所构建pTrxA-gD1重组表达质粒阳性克隆经PCR与双酶切鉴定,与预期结果一致;含有pTrxA-gD1重组质粒的大肠杆菌Rosetta诱导后得到了高效达,SDS-PAGE显示表达产物约Mr48000（Dalton）。免疫印迹结果表明表达产物具有较好的抗原性。结论　成功构建了pTrxA-gD1表达质粒,实现了成熟gD1蛋白在大肠杆菌中的高效表达,表达产物具有好的抗原性。     

鹅IL-2基因在大肠杆菌中的表达及其可溶性单体的分离

将去除信号肽编码序列的鹅IL-2基因克隆到原核表达载体pET-28a (+), 构建了重组表达质粒pET-28a (+)-goIL-2, 转化大肠杆菌BL21(DE3)感受态细胞, 经IPTG诱导, 实现了重组鹅IL-2(rgoIL-2)蛋白在大肠杆菌中的表达。SDS-PAGE和Western-blotting分析显示, 表达蛋白的分子量约为15.0 kD, 能被抗鹅IL-2单克隆抗体特异识别。可溶性分析表明表达蛋白大部分以包涵体形式存在, 部分以可溶形式存在, 非变性电泳可见可溶性蛋白存在单体和多聚体组分。镍柱亲和层析法纯化的rgoIL-2蛋白过滤后, 利用?KTA FPLC(快速蛋白分离纯化系统)进行逐级分离, 非变性电泳可见单一的鹅IL-2可溶性蛋白单体。体外生物学活性分析显示鹅IL-2可溶性蛋白单体能刺激鹅淋巴细胞增殖。这为进一步研究鹅IL-2的生物学功能及其临床应用奠定基础。     

拟南芥中柯浩体蛋白Atcoilin的克隆、表达及纯化

旨在制备柯浩体的标志蛋白——Atcoilin蛋白,利用pET-28a与目的基因构建重组表达质粒,经DNA测序证实插入序列与设计完全一致后,将重组质粒转化大肠杆菌BL21(DE3),用IPTG进行诱导表达,产物用SDS-PAGE及Western blotting分析鉴定。通过分别改变IPTG的浓度、培养时间、培养温度等来优化Atcoilin蛋白的表达条件。表达出的重组蛋白经过镍柱、分子筛进行纯化。结果显示,原核表达载体pET28a-At1g13030成功构建,可在大肠杆菌BL21(DE3)中诱导表达,得到相应的重组蛋白经Western blotting鉴定正确。在IPTG浓度为0.7 mmol/L,18℃培养20 h的条件下,目的蛋白表达量最高。经过SDS-PAGE分析鉴定,过镍柱、分子筛后得到的重组蛋白纯度较高。     

GST-Exendin-4在大肠杆菌中的可溶性表达和纯化

为了制备GST-Exendin-4融合蛋白,以本实验室构建好的pET22b-Exendin-4为模板,通过PCR扩增出Exendin-4基因,酶切克隆入pGEX-4T-1,构建重组表达质粒pGEX-4T-1-Exendin-4.经DNA测序证实插入序列与设计完全一致后,将重组质粒转化大肠杆菌BL21(DE3),在不同浓度的IPTG和不同温度诱导下,经SDS-PAGE分析鉴定,表达出Mr约为30 kD的目的蛋白,灰度扫描显示目的蛋白占菌体总蛋白的29.9%,超声裂解后的上清通过Sepharose 4B亲和层析纯化、透析、除盐及冷冻干燥得到高纯度的目的蛋白.本研究成功制备了高纯度的GST-Exendin-4融合蛋白,为下一步进行目的蛋白大规模的生产打下了良好的基础.     

拟南芥DBB 1 a（double B-box 1a）蛋白的表达、纯化及Western blotting检测

PCR扩增拟南芥（Arabidopsis thaliana）DBB1a cDNA的保守区段（GenBank登录号：AT2G21320）,转化到冷诱导表达载体pCold TF上,构建pCold-DBB1a重组质粒,转化大肠杆菌DH5a.15℃下IPTG诱导表达融合蛋白,并通过SDS-PAGE检测.证实目的蛋白以可溶形式在约20 kD处高效表达,与预期蛋白大小相吻合.表达蛋白经Ni琼脂糖凝胶亲和层析纯化,SDS-PAGE及Western blotting检测证实纯化后获得高纯度融合蛋白,这为进一步研究DBB1a功能奠定了基础.     

小鼠IL-35基因毕赤酵母表达载体的构建及表达

目的构建真核酵母表达载体pPIC9K与小鼠IL-35基因的重组质粒pPIC9K-mIL-35-His,在毕赤酵母GS115菌株中诱导表达,并对其进行鉴定。方法以pET-30a-mIL-35为模板,用PCR扩增出IL-35去信号肽基因全序列,并在3'端引入His标签,构建重组质粒pPIC9K-mIL-35-His,经SalⅠ线性化重组质粒后,用电穿孔方法将该基因转染毕赤酵母细胞内。经G418梯度筛选高拷贝转化子,筛选Mut+表型后经PCR进一步鉴定IL-35基因与酵母染色体是否整合。小量诱导表达筛选出高表达菌株,大量甲醇诱导表达,以SDS-PAGE及免疫印迹(Western blot)鉴定蛋白表达。结果小鼠IL-35基因真核酵母表达载体pPIC9K-mIL-35-His构建成功,并且在GS115中通过甲醇诱导表达,经SDS-PAGE及Western blot分析,可见相对分子质量约为65 000的目的蛋白。结论实验所构建的重组质粒pPIC9K-mIL-35-His可在毕赤酵母GS115中正确的表达小鼠IL-35基因。     

烟草SKP1基因的原核表达

为获取大量高纯度的枯斑三生烟SKP1蛋白以便研究其功能和性质,以pMD18-SKP1质粒为模板, PCR扩增枯斑三生烟的SKP1基因的cDNA编码区,经酶切后构建表达载体pET23b-SKP1,转入大肠杆菌BL21(DE3)进行诱导表达,并考察不同的IPTG诱导终浓度、表达时间和表达温度对目的蛋白His-SKP1表达量的影响.SDS-PAGE分析结果表明:最佳表达条件为不加诱导剂的情况下,37℃表达8 h.     

HCV核心蛋白在大肠杆菌中的表达及免疫学特性分析

目的:表达HCV核心蛋白,为检测丙肝病毒提供合适抗原。方法:以含HCV核心全长cDNA克隆的pMD18T/core质粒为模板,PCR扩增全长的HCV核心抗原基因,插入表达载体pQEN1构建重组质粒pQEN1/Core,转化BL-21(DE3)大肠杆菌,IPTG诱导表达6×His融合蛋白,表达产物经SDS-PAGE及Western blot检测和鉴定。结果:经SDS-PAGE及Western blot显示HCV核心蛋白在大肠杆菌中正确表达,融合蛋白分子量约为22 kD,表达量约占菌体蛋白总量的30%。纯化后的C蛋白能与慢性丙型肝炎患者有血清反应。结论:HCV核心蛋白在大肠杆菌中成功表达并具有较强的抗原性。     

人IL-3基因原核表达载体的构建及表达

目的：构建人IL-3基因原核表达载体pET32a-IL-3,并在大肠杆菌中诱导表达。方法：通过佛波酯（TPA）和植物球血凝素（PHA）刺激人T淋巴细胞系Jurkat细胞,增加IL-3mRNA表达水平,提取mRNA,逆转录-聚合酶链反应（RT-PCR）获得cDNA,以Jurkat细胞cDNA为模板,通过PCR方法扩增得到人IL-3基因,将其克隆入原核表达载体pET32a（＋）中,将重组质粒转化入大肠杆菌宿主菌株BL21中,以异丙基硫代半乳糖苷（IPTG）诱导融合蛋白表达,并通过改变IPTG浓度,诱导时间,诱导温度等条件最终实现蛋白的可溶性表达。表达产物用SDS-PAGE检测表达情况。结果：酶切鉴定和测序结果证明成功构建了原核表达载体pET32a．IL-3。SDS-PAGE检测结果证明实现了人IL-3基因在大肠杆菌中的可溶性表达。结论：成功构建了人IL-3基因的原核表达载体并在大肠杆菌中获得了良好的表达。     

Expression and characterization of human glycosylated interleukin-1 receptor antagonist in Pichia pastoris

Interleukin-1 receptor antagonist is an inhibitor of the pro-inflammatory action of interleukin-1. The gene encoding for interleukin-1 receptor antagonist (IL-1ra) was cloned into a Pichia pastoris expression vector pPICzalphaA (Invitrogen, USA) and transformed into P. pastoris strain SMD1168H. Multi-copy selection of the gene produced a high expressing strain of IL-1ra that produced 17mg/L of total secreted purified protein. The IL-1ra produced in P. pastoris was a mixture of glycosylated and non-glycosylated IL-1ra where 70% of the total protein was glycosylated. SP-Sepharose purification allowed for separation of the two expressed forms of IL-1ra, which permits biochemical investigation of glycosylated and non-glycosylated IL-1ra using one expression system. Mass spectrometric analysis revealed the expression of the full-length protein and that the glycosylated IL-1ra contained high mannose glycoforms that ranged from Man(9)GlcNAc(2) to Man(14)GlcNAc(2).     

Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor.

The objective of these experiments was to evaluate the production of IL-1ra, a specific receptor antagonist of IL-1, by human in vitro-derived macrophages, a model for differentiated macrophages. IL-1ra protein levels in supernatants and lysates of cultured cells were determined by a specific ELISA. Relative steady-state IL-1ra mRNA levels were measured using a specific cDNA probe. Human monocytes were differentiated by 6 days culture in either medium or granulocyte-macrophage colony-stimulating factor (GM-CSF), after which the effects of subsequent LPS and/or GM-CSF on the production of IL-1ra were evaluated. In vitro-derived macrophages cultured in medium for 6 days constitutively produced IL-1ra protein during the 24-h period of the 7th day in culture. The constitutive production of IL-1ra by medium-aged cells correlated with low steady-state IL-1ra mRNA levels determined over this same time period. In contrast, cells cultured for 6 days in GM-CSF synthesized significantly increased levels of IL-1ra protein during the 7th day in culture but the secreted levels remained unchanged. Cells differentiated in GM-CSF displayed enhanced steady-state levels of IL-1ra mRNA in comparison with cells aged in medium. Stimulation of in vitro-derived macrophages aged for 6 days in medium or in GM-CSF, with LPS or adherent IgG, did not result in increased levels of IL-1ra protein production in comparison with non-LPS stimulated cells. The IL-1ra protein detected in the supernatants of cells differentiated in GM-CSF was biologically active in the IL-1-augmented murine thymocyte proliferation assay. By Western blot analysis, the IL-1ra protein in the in vitro-derived macrophage supernatants was predominantly the 22- to 24-kDa glycosylated species, whereas the lysates contained additional lower molecular weight forms. These results suggest that as monocytes differentiate in vitro into macrophages, they constitutively produce IL-1ra protein and that this production is enhanced by the continuous presence of GM-CSF.     

Altered interleukin-1 receptor antagonist and interleukin-18 mRNA expression in myocardial tissues of patients with dilatated cardiomyopathy

Interleukin-1 (IL-1) is a potent regulator of cell proliferation, inflammation, and contraction of cardiovascular cells. It has been proposed that the IL-1/IL-1ra (IL-1 receptor antagonist) ratio influences these functions. Other members of the IL-1 family and the related caspase-1 also contribute to regulation of IL-1-mediated functions. We determined the mRNA expression of caspase-1, caspase-3, IL-1alpha , IL-1beta , IL-18, IL-1 receptor type I (IL-1-RI), and IL-1ra in left ventricle tissue of hearts from patients with ischemic or dilated cardiomyopathy (ICM or DCM) and in control tissues from unused donor transplant hearts in RT-PCR experiments. We show that the expression of caspase-1, caspase-3, IL-1beta , and IL-1-RI mRNA was not different between patients and control tissues. Furthermore, we did not find detectable amounts of IL-1alpha mRNA in any of these adult myocardial tissues. On the other hand, expression of IL-18 RNA was lower in myocardium of both patient groups compared with control hearts. Furthermore, IL-1ra mRNA expression was significantly lower in tissues of DCM patients compared with ICM patients and controls. This was in line with a trend towards lower IL-1ra protein levels in myocardial tissues of DCM patients. In contrast with the adult tissues discussed above, which did not express IL-1alpha mRNA, commercially available human fetal tissue expressed IL-1alpha mRNA. On the other hand IL-1beta mRNA was present in fetal and in adult human heart tissue. Our data provide evidence for an altered ratio of IL-1/IL-1ra in DCM patients. This dysregulation may contribute to pathogenesis and/or progression of heart disease by modulating the otherwise balanced IL-1-mediated functions in cardiovascular cells.     

Interleukin 1 receptor antagonist in human epidermis and cultured keratinocytes.

Interleukin 1 (IL-1), present in high amounts in normal human skin without any sign of inflammation, suggests a complex mechanism by which its bioactivity is regulated. The specific receptor antagonist of IL-1 (IL-1ra) was analyzed in human skin, sweat and cultured keratinocytes. Extracts of both skin and cultured keratinocytes blocked the binding of [125I]IL-1 to its receptor whereas sweat did not. The inhibitory activity was cell-associated, was not secreted by cultured keratinocytes, and IL-1ra mRNA was identified in these cells. There was an inverse relationship between the level of IL-1ra and that of IL-1 alpha and beta since extracts of differentiating keratinocytes (DK) and higher IL-1ra levels and expressed more mRNA for IL-1ra than non-differentiated keratinocytes (NDK), whereas NDK contained 4 times more IL-1 alpha and beta proteins than DK. This association of cell differentiation with a shift in agonist/antagonist ratio might be related to important autocrine or paracrine functions of IL-1 in normal and inflamed human skin.     

Effects of physical training on IL-1beta, IL-6 and IL-1ra concentrations in various brain areas of the rat

There is increasing evidence that voluntary physical activity and exercise training have beneficial effects on brain function by facilitating neurovegetative, neuroadaptative and neuroprotective processes. Cytokines are chronically expressed at elevated levels within the CNS in many neurological disorders and may contribute to the histopathological, pathophysiological, and cognitive deficits associated with such disorders. In the present study, we examined the influence of seven weeks of physical training on IL-1b, IL-6 and IL-1ra concentrations in hypothalamus, pituitary, hippocampus, cerebellum and frontal cortex in rats. We determined circulating concentrations of cytokines, corticosterone, prolactin and leptin. Two groups of 10 rats were investigated: one group (trained rats) was progressively trained (5 days/week); the other group (sedentary rats) was used as a sedentary group. The training program induced a decrease of (i) IL-1b concentration in the hippocampus (0.7 +/- 0.16 versus 0.99 +/- 0.14 pg/mg protein; p < 0.05), (ii) IL-6 concentration in the cerebellum (10.7 +/- 1.00 in trained rats versus 14.8 +/- 1.34 pg/mg protein in sedentary rats; p < 0.05), (iii) IL-1ra concentration in the pituitary (245 +/- 14.31 versus 328 +/- 17.73 pg/mg protein; p < 0.01). We also found positive correlations between (i) serum prolactin and the concentration of IL-6 in the cerebellum, (ii) serum leptin and the concentration of IL-1ra in the pituitary. There was no effect of physical training on IL-1b, IL-6, and IL-1ra serum levels. These findings suggest that the decrease in particular pro-inflammatory, central cytokines such as IL-1b and IL-6 induced by the training program may play a role in the positive effects of regular physical activity on the central nervous system.     

Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra

A complete understanding of the role for endogenously produced interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), and IL-1 receptor antagonist (IL-1ra) in the acute phase response to inflammation remains unknown. In the present studies, knockout mice lacking either a functional IL-1 type I receptor (IL-1RI(-/-)), a TNF type I receptor (TNFR-I(-/-)), or both IL-1 type I and TNF type I receptors (IL-1RI(-/-)/TNFR-I(-/-)) received a turpentine abscess. Additional mice deficient in IL-1ra protein (IL-1ra(-/-)) or overexpressing IL-1ra protein (IL-1ra(tg)) were similarly treated. After a turpentine abscess, IL-1 receptor knockout mice exhibited an attenuated inflammatory response compared with wild-type or animals lacking a functional TNFR-I. Mice overexpressing IL-1ra also had an attenuated hepatic acute phase protein response, whereas IL-1ra knockout mice had a significantly greater hepatic acute phase response. We conclude that the inflammatory response to a turpentine abscess is the result of a balance between IL-1ra expression and IL-1 binding to its type I receptor. Endogenously produced IL-1ra plays a central role in mitigating the magnitude of the IL-1-mediated inflammatory response and, ultimately, the outcome to a turpentine abscess.     

IL-1ra突变体的构建、表达及初步的药代动力学分析

白细胞介素1受体拮抗剂(Interleukin1 receptor antagonist,IL-1ra)是IL-1家族的一员,由于它可以特异性地抑制IL-1的生物学效应,因此在类风湿性关节炎(Rheumatoid Arthritis,RA)的治疗中倍受重视。为了提高IL-1ra的代谢稳定性,利用Ala代替其序列中的双碱性氨基酸,构建了3个突变体,分别为IL-1ra-1(R6K7-AA),IL-1ra-2(R93K94-AA),IL-1ra-3(K97R98-AA);将突变后的序列插入表达载体pTIG-Trx,转化大肠杆菌BL21(DE3);利用Ni2 金属螯合层析,SephadexG75凝胶过滤纯化表达产物;体外活性检测的结果表明,3个突变体的生物学活性与IL-1ra相比没有显著性差别(P=0·2248);初步的药代动力学分析结果显示:3号突变体IL-1ra-3的半衰期与IL-1ra相比提高了2·26倍。     

Cloning and chromosome mapping of the human interleukin-1 receptor antagonist gene.

By screening a human genomic library with an interleukin-1 receptor antagonist (IL-1ra) cDNA probe, we have isolated a 15 kb clone which contains the entire coding region of the gene as expressed in monocytes, and includes 6 kb of 5'-upstream sequence. The gene contains four exons which code for the secreted form of the IL-1ra, however, our clone does not contain the alternative first exon used to generate an intracellular form of the protein as the protein as found in epithelial cells. Analysis of the sequence reveals a consensus TATA box, and three Alu repeats, two of which are in the upstream region and one in intron 3. The sequence also reveals an 86 bp motif tandomly repeated four times within intron 2, and may reflect the polymorphism known to exist in this region of the gene. By in-situ fluorescence hybridization we have shown that the IL-1ra gene is found on the long arm of chromosome 2 and maps to 2q13-14.1. Previous studies have revealed that IL-1 alpha, and IL-1 beta and both type I and type II forms of the IL-1 receptor all map close to this region of chromosome 2.     

Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction.

The interleukin-1 receptor antagonist (IL-1ra) is a protein capable of inhibiting receptor binding and biological activities of IL-1 without inducing an IL-1-like response. Equilibrium binding and kinetic experiments show that IL-1ra binds to the 80-kDa IL-1 receptor on the murine thymoma cell line EL4 with an affinity (KD = 150 pM) approximately equal to that of IL-1 alpha and IL-1 beta for this receptor. However, IL-1ra is unable to induce two early events associated with IL-1 activity. Surface-bound IL-1ra does not undergo receptor-mediated internalization, and IL-1ra does not activate the protein kinase activity responsible for down-modulation of the EGF receptor on the murine 3T3 fibroblast cell line. The failure to induce general, early responses characteristic of IL-1 indicates that IL-1ra is unlikely to act as an agonist on any cell expressing the 80-kDa receptor.